Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Lenvatinib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Lenvatinib as a study intervention. Browse Lenvatinib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
156
Shown on this page
12
Current sort
Recently updated
Therapy scope
Lenvatinib
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Lenvatinib. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 73–84 of 156 matching trials for Lenvatinib.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Recruiting Phase 2 Interventional

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

NCT05746208
View directory record Official record
Conditions
Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site
Interventions
Lenvatinib, Pembrolizumab, Hyperpolarized 13C-Pyruvate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 17, 2026, 9:27 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma

NCT05147558
View directory record Official record
Conditions
Uterine Carcinosarcoma, Advanced Uterine Carcinosarcoma
Interventions
Pembrolizumab, Lenvatinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 17, 2026, 9:27 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

NCT02811861
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Lenvatinib, Everolimus, Pembrolizumab, Sunitinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,069 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
35
States / cities
Stanford, California • Boca Raton, Florida • Fort Myers, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 17, 2026, 9:27 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

NCT03829332
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pembrolizumab, Lenvatinib, Placebo for lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
Anchorage, Alaska • Chandler, Arizona • Bakersfield, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 17, 2026, 9:27 AM EDT
Active, not recruiting Phase 2 Interventional

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT04781088
View directory record Official record
Conditions
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Lenvatinib, Paclitaxel, Pembrolizumab
Drug · Biological
Lead sponsor
Floor Backes, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 17, 2026, 9:27 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

NCT03820986
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Pembrolizumab, Lenvatinib, Placebo for lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 17, 2026, 9:27 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

NCT03713593
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
lenvatinib, pembrolizumab, saline placebo
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
21
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 17, 2026, 9:27 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

NCT03829319
View directory record Official record
Conditions
Nonsquamous Non-small Cell Lung Cancer
Interventions
Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed, Lenvatinib, Placebo matching lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
761 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
17
States / cities
Mountain View, California • New Haven, Connecticut • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 17, 2026, 9:27 AM EDT
Completed Phase 3 Interventional Results available

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

NCT03898180
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Pembrolizumab, Lenvatinib, Placebo for lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
21
States / cities
Gilbert, Arizona • Clovis, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 17, 2026, 9:27 AM EDT
Completed Phase 3 Interventional Results available

Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

NCT04776148
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
pembrolizumab, lenvatinib, regorafenib, TAS-102 (trifluridine and tipiracil)
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Monterey, California • Marietta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 17, 2026, 9:27 AM EDT
Completed Phase 3 Interventional Results available

Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)

NCT03884101
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
Lenvatinib, Pembrolizumab, Paclitaxel, Carboplatin
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
842 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
29
States / cities
Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 17, 2026, 9:27 AM EDT
Recruiting Early Phase 1 Interventional

Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

NCT05553782
View directory record Official record
Conditions
Salivary Gland Cancer, Adenoid Cystic Carcinoma of the Salivary Gland, Squamous Cell Carcinoma of Head and Neck, Head and Neck Cancer
Interventions
Implantable Microdevice (IMD)
Combination Product
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 17, 2026, 9:27 AM EDT

About this Lenvatinib clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Lenvatinib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lenvatinib.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Lenvatinib.